1V-LSD (1-valeryl-LSD, also known as Valerie) is a synthetic psychedelic of the lysergamide family and an N1-acylated derivative of LSD featuring a valeryl (5-carbon) group at position 1 of the lysergamide nitrogen. Like other members of the 1-acyl LSD series, 1V-LSD is believed to function as a prodrug for LSD, with esterase-mediated cleavage of the valeryl ester releasing LSD in vivo. The subjective experience is therefore expected to be the full LSD experience, with the primary distinction being a delayed onset relative to LSD blotter.
Community reports describe 1V-LSD onset at approximately 75–100 minutes, somewhat longer than the 60–75 minutes typically reported for 1cP-LSD or 1P-LSD, which may reflect slower esterase hydrolysis of the larger valeryl group compared to shorter-chain acyl groups. Once fully active, the experience is described as indistinguishable from LSD, lasting 8–12 hours with the full character of LSD including visual phenomena, cognitive expansion, emotional amplification, and potential ego dissolution at sufficient doses.
1V-LSD appeared in the research chemical market in the early 2020s, as part of the continuing series of N1-acyl LSD analogs introduced in response to regulatory action against earlier members. It gained the informal name "Valerie" in community parlance, continuing the naming conventions established for other members of the series. Community experience is thinner than for 1P-LSD or 1cP-LSD, making the knowledge base for dosing, effects, and safety somewhat less mature.
Testing with Ehrlich reagent is essential before use. All LSD contraindications, harm reduction practices, and emergency protocols apply identically to 1V-LSD given the prodrug relationship.
Safety at a Glance
High Risk- Ehrlich reagent confirms indole compound (purple/violet). Essential before any 1V-LSD use.
- Assumed equivalent potency to LSD:
- Toxicity: Acute Toxicity Expected identical to LSD: extremely low pharmacological toxicity. No documented fatalities from 1V-LS...
- Overdose risk: Overdose 1V-LSD has no known toxic dose. However, higher doses increase the risk of adverse psych...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 8 hrs – 12 hrsHow It Feels
There is a period of waiting that feels longer than it is. The valeroyl ester must be cleaved by the body before the lysergic acid diethylamide beneath can begin its work, and this metabolic preamble adds a buffer of twenty to forty minutes during which anticipation is the dominant experience. Then, gradually, the world begins to change.
The first signs are physical. A gentle tightening through the core, a heightened sensitivity in the skin, a subtle shift in the weight of your own body. Light begins to behave differently, acquiring a faint prismatic quality at the edges. Sound seems to gain depth and spatial presence. These early changes are indistinguishable in character from LSD; the molecule, once freed from its prodrug shell, follows the same neurochemical pathways and speaks the same perceptual language.
The peak builds over one to two hours into full lysergic territory. The visual field becomes a living canvas: surfaces undulate with organic breathing patterns, geometric overlays appear on textures and in peripheral vision, and closed-eye space unfolds into elaborate, self-generating mandalas of color and form. The cognitive experience is expansive and often profound. Familiar assumptions about self, relationships, and the nature of experience come up for re-examination. Thoughts branch into recursive loops that can feel either illuminating or destabilizing depending on setting and intention. Emotionally the range is vast: moments of transcendent beauty sit alongside passages of vulnerability and occasionally raw confrontation with suppressed material.
Coming down, the intensity recedes in slow, overlapping waves. Visuals simplify from baroque complexity to gentle breathing and enhanced color saturation. The mind begins to gather itself, reassembling linear thought from the scattered fragments of the peak. There is often a long plateau of mild alteration, a window of several hours during which reality feels cleansed and luminous. Eventually the body relaxes, the jaw unclenches, and sleep becomes possible, though it may carry vivid and unusually narrative dreams.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(20)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Physical fatigue— Physical fatigue is a state of bodily exhaustion characterized by reduced energy, diminished capacit...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(19)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Peripheral vision changes— Alterations in side vision ranging from enhanced peripheral awareness to tunnel vision, with charact...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(28)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Ego replacement— Ego replacement is the experience of one's usual personality and sense of self being completely over...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Multiple thought streams— The experience of having more than one internal narrative or stream of consciousness simultaneously ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Personal meaning enhancement— Personal meaning enhancement is a state in which everyday events, coincidences, song lyrics, environ...
- Personality regression— Personality regression is a state in which a person temporarily adopts the cognitive patterns, emoti...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Suggestibility enhancement— Heightened receptivity to external suggestions, ideas, and influence, commonly experienced during ps...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought disorganization— Thought disorganization is a cognitive impairment in which the normal capacity for structured, seque...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(3)
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
1V-LSD acts as a prodrug for LSD via esterase-mediated hydrolysis of the N1-valeryl ester bond, releasing LSD which then exerts the full LSD pharmacological profile. Primary action is partial agonism at cortical 5-HT2A receptors with biased β-arrestin signaling, disrupting normal predictive-coding hierarchies and producing the characteristic psychedelic alterations.
The valeryl group (5 carbons) is the largest of the common N1-acyl LSD series, and its greater size and lipophilicity relative to propionyl or cyclopropanoyl groups may modestly slow esterase hydrolysis, contributing to the longer onset reported by community members.
Receptor Targets (via LSD)
- 5-HT2A receptors — primary psychedelic target; partial agonist; biased β-arrestin activation
- 5-HT1A receptors — partial agonist; anxiolytic and introspective modulation
- 5-HT2C receptors — agonist activity; anxiogenic potential at high doses
- Dopamine D2/D3 receptors — stimulant and mood-amplifying component
- α-adrenergic receptors — sympathomimetic effects
Pharmacokinetics
Community-reported onset of 75–100 minutes suggests a slower conversion rate than shorter-chain analogs. Peak effects expected at 2.5–4 hours. Total duration 8–12 hours, consistent with LSD. No formal human pharmacokinetic data for 1V-LSD are available.
Tolerance
Identical to LSD: rapid functional tolerance within 24–48 hours, complete cross-tolerance with serotonergic psychedelics, reversal over 5–7 days.
Detection Methods
Urine Detection
1V-LSD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for 1V-LSD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
1V-LSD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for 1V-LSD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
1V-LSD appeared in the research chemical market in approximately 2021, part of the continuing series of N1-acyl LSD analogs. The valeryl group was selected to produce a structurally distinct compound following earlier members of the series facing regulatory action. Like other members of the series, it was designed to occupy the legal space between explicitly controlled analogs while delivering equivalent effects through prodrug conversion.
Naming
1V-LSD received the informal name "Valerie" in research chemical communities, consistent with the practice of giving lysergamide analogs female names (alongside "Curie" for 1cP-LSD).
Legal Status
Germany has been at the forefront of scheduling 1-acyl LSD series compounds, scheduling multiple members. The United Kingdom's Psychoactive Substances Act 2016 covers 1V-LSD. Legal status varies substantially by jurisdiction and changes frequently as regulatory bodies respond to new analogs.
Harm Reduction
Testing
Ehrlich reagent confirms indole compound (purple/violet). Essential before any 1V-LSD use.
Dosing
Assumed equivalent potency to LSD:
- Threshold: 15–25 μg
- Light: 25–75 μg
- Common: 75–150 μg
- Strong: 150–300 μg
The longer onset (75–100 minutes) makes this compound particularly prone to premature redosing errors. Community reports emphasize patience — wait at least 90–120 minutes before concluding that effects are not developing.
Set and Setting
- Stable mental state; familiar, safe, comfortable environment
- Trip sitter strongly recommended; plan full day and following day
- Avoid use during psychological stress, grief, or major life disruptions
Dangerous Combinations
- Lithium — contraindicated; seizure and cardiac events with lysergamides
- MAOIs — serotonin syndrome risk
- Tramadol — seizure risk
- Cannabis — unpredictable amplification
- Stimulants — cardiovascular and psychological intensity amplification
Emergency Protocol
- Environment change, grounding techniques (cold water, slow breathing, trusted contact)
- Benzodiazepines (diazepam 10–20 mg) for acute distress
- Emergency services for physical safety concerns
Toxicity & Safety
Acute Toxicity
Expected identical to LSD: extremely low pharmacological toxicity. No documented fatalities from 1V-LSD. Primary risks are psychological.
Cardiovascular Effects
LSD-equivalent: mild tachycardia, blood pressure elevation, mydriasis, peripheral vasoconstriction. Individuals with cardiovascular disease should not use lysergamide compounds.
Psychological Risks
- Acute anxiety and panic — dose-dependent; community reports for 1V-LSD mirror LSD in character
- Psychosis induction — absolute contraindication with history of schizophrenia or bipolar I
- HPPD — risk with any serotonergic psychedelic at sufficient dose frequency
Contraindications
Personal or family history of psychosis or bipolar disorder; lithium, MAOI, antipsychotic, or tramadol use; cardiovascular disease; pregnancy.
Overdose
No pharmacological overdoses documented. Benzodiazepines are first-line for acute psychological distress.
Addiction Potential
non-addictive with a low abuse potential
Overdose Information
Overdose
1V-LSD has no known toxic dose. However, higher doses increase the risk of adverse psychological reactions. These reactions include anxiety, delusions, panic attacks and, more rarely, seizures. Medical attention is usually not needed except in the case of severe psychotic episodes or the ingestion of fake acid (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the acute negative cognitive effects of 1V-LSD.
Although no formal studies have been conducted, it is assumed that like LSD itself, 1V-non-addictive with a low abuse potential.
There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.
Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped. It is assumed that 1V-LSD shares these properties with LSD.
Tolerance to the effects of 1V-almost immediately after ingestion. After that,5-714 days to be back at baseline (in the absence of further consumption). 1V-LSD produces cross-tolerance with Cross-all psychedelics, meaning that after the use of 1V-LSD they will have a reduced effect.
The following substances are listed on the assumption that 1V-LSD possesses a similar if not the same dangerous interactions profile as LSD, and may include more due to its status as an unstudied research chemical.
Internationally, 1V-LSD is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area in many countries, meaning that while it is not specifically illegal, individuals may still be cha
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
Internationally, 1V-LSD is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area in many countries, meaning that while it is not specifically illegal, individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Austria: 1V-LSD is technically not illegal but it may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD, thus making it illegal to supply for human consumption.
Czech Republic: 1V-LSD is not scheduled as a controlled substance in the Czech Republic as of June 05, 2025.
Germany: 1V-LSD is controlled under the NpSG (New Psychoactive Substances Act) as of October 7, 2022. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: 1V-LSD is a controlled substance in Japan as of March 20, 2023.
Latvia: 1V-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Switzerland: 1V-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.
Turkey: 1V-LSD is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 1V-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.
United States: Since 1V-LSD can be considered a prodrug for LSD, its possession and sale may be prosecutable in the United States under the Federal Analogue Act.
LSD
Psychedelics
Research chemicals
Responsible use
Discussion
The Small & Handy 1V-LSD Thread (Bluelight)
Experience Reports (1)
Tips (3)
Have a trip sitter present, ideally someone with psychedelic experience. They should remain calm and reassuring without being intrusive. A good sitter can make the difference between a challenging experience and a genuine crisis.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 1V-LSD and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
If you experience anxiety or thought loops on 1V-LSD, change your physical environment: move to a different room, go outside, change the music, or hold something cold. A change of scenery can instantly shift a difficult headspace.
See Also
Similar by Effects
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 1V-LSD - TripSit Factsheet
TripSit factsheet for 1V-LSD
tripsit - 1V-LSD - Wikipedia
Wikipedia article on 1V-LSD
wikipedia